Search clinical trials for: Adjuvant treatment:afatinib

Total 8229 results

Tang-Du Hospital

Recruiting

Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC

Carcinoma, Non-Small-Cell Lung | Neoplasm, Residual | Circulating Tumor DNA | Next-Generation Sequencing | Chemotherapy, Adjuvant

China
GlaxoSmithKline

Recruiting

A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

Hepatitis B

Germany, United Kingdom, Belgium
GlaxoSmithKline

Active, not recruiting

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Cytomegalovirus Infections

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

Herpes Simplex

Germany, United States, Belgium, Canada, Spain, United Kingdom, Estonia, Australia
Immune Response BioPharma, Inc.
cro

Unknown

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis

United States
Epimmune

Unknown

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
University of Maryland, Baltimore
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Prostate Cancer
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

United States
University of Oxford
European and Developing Countries Clinical Trials Partnership (EDCTP); Kenya...

Completed

A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and Infants

Malaria,Falciparum

Kenya
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

Influenza

Germany
Merck Sharp & Dohme LLC

Completed

Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)

Dengue
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
Curevo Inc
Green Cross Corporation; Mogam Biotechnology Research Institute

Active, not recruiting

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Herpes Zoster | Shingles

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage II Pancreatic Cancer | Stage IVA Pancreatic Cancer | Stage IVB Pancreatic Cancer | Stage I Pancreatic Cancer | Stage II Non-small Cell Lung Cancer | Stage III Colon Cancer and other conditions

United States
QLT Inc.

Completed

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
Fifth Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation (Neoafa)

Chemotherapy | Surgery | Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR TKI
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Advanced Melanoma (Mel48)

Intraocular Melanoma | Malignant Conjunctival Neoplasm | Melanoma (Skin)

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin) | Non-melanomatous Skin Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Melanoma (Skin)

United States
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer

Breast Cancer

United States
The Vaccine Company

Unknown

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
PATH
GlaxoSmithKline; Icahn School of Medicine at Mount Sinai; Duke University; Children... and other collaborators

Completed

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Influenza | Vaccine

United States
Jiangsu Province Centers for Disease Control and...
Bejing Vigoo Biological Co., LTD

Completed

A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children

EV71-associated Disease

China
TVAX Biomedical

Completed

Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma

Glioma | Glioblastoma Multiforme | High Grade Astrocytoma

United States
Centre Hospitalier Universitaire Vaudois

Completed

Immunotherapy of Melanoma Patients

Melanoma

Switzerland
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV

Nonneoplastic Condition

United States
Clover Biopharmaceuticals AUS Pty Ltd

Completed

SCB-2019 as COVID-19 Vaccine

COVID-19

Australia
University of Southern California
National Cancer Institute (NCI)

Completed

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
MabVax Therapeutics, Inc.

Completed

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Sarcoma

United States
The University of Texas Medical Branch, Galveston
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Intestine Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
GlaxoSmithKline
Biological E. Limited

Recruiting

Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

Typhoid Fever

Belgium
BiondVax Pharmaceuticals ltd.

Completed

A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers

Influenza

Israel
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Innovive Pharmaceuticals

Completed

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Myelodysplastic Syndromes | Leukemia | Lung Cancer | Malignant Mesothelioma | Primary Peritoneal Cavity Cancer

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
GlaxoSmithKline

Unknown

Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
National Institute of Allergy and Infectious Diseases...
Emory University

Completed

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Influenza A Virus, H5N1 Subtype

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (DPIV-001)

Dengue Fever

United States
Immune Response BioPharma, Inc.

Not yet recruiting

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

Multiple Sclerosis

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
University of Illinois at Chicago
National Cancer Institute (NCI)

Completed

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) (DPIV-002)

Dengue Fever

Puerto Rico
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States

Search clinical trials for: Adjuvant treatment:afatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations